Genetic Markers of Circulating Tumor DNA for Monitoring Breast Cancer Patients in Costa Rica

NCT04163159 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2019-11-25

No results posted yet for this study

Summary

The use of circulating tumor DNA (ctDNA) as a noninvasive test for breast cancer monitoring throughout the course of the disease

Conditions

Sponsors & Collaborators

  • Universidad de Costa Rica

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-07
Primary Completion
2020-10-31
Completion
2020-11-30

Countries

  • Costa Rica

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04163159 on ClinicalTrials.gov